Summary sheet
The project will finance the promoter's research, development and innovation (RDI) investments to develop a pipeline of proprietary gene therapy candidates.
The company is developing a pipeline of proprietary gene therapy candidates to provide patients with a long-lasting cure for severe genetic blinding retinal diseases, for which there are currently no approved treatments.
The project concerns an operation under the European Growth Finance Facility. The purpose of the loan is to provide direct, equity-type financing under EIB's Venture Debt Instrument to support Research, Development and Innovation ("RDI") activities of the innovative company 'Gensight', an SME based in France. The financing of this project addresses the failure in financial markets for RDI, arising from limited access to commensurate financing as a result of factors such as information asymmetries, misalignment of incentives, etc. Gensight is a clinical-stage biopharmaceutical company focused on the development of gene therapies with the potential to provide patients with a long-lasting cure for severe genetic blinding retinal diseases. If successful, the project will have a high socio-economic impact. In addition, by creating knowledge externalities, the project will provide significant socio-economic benefits, will strengthen France and Europe's leading position in biotechnologies, and it will help to retain skilled staff engaged in the Company's RDI activities.
The related RDI investments are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during appraisal.
The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the project procurement procedures are expected to be in line with EIB guidelines for private sector projects. The EIB will verify details during the project due diligence.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
Documents
News & Stories
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications